200 related articles for article (PubMed ID: 32852167)
1. [Management of patients with type 2 diabetes at cardiovascular and renal risk : ESC versus ADA-EASD].
Scheen AJ; Paquot N
Rev Med Suisse; 2020 Aug; 16(703):1478-1482. PubMed ID: 32852167
[TBL] [Abstract][Full Text] [Related]
2. Use of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists according to the 2019 ESC guidelines and the 2019 ADA/EASD consensus report in a national population of patients with type 2 diabetes.
Lim CE; Pasternak B; Eliasson B; Danaei G; Ueda P
Eur J Prev Cardiol; 2023 Jun; 30(8):634-643. PubMed ID: 36582120
[TBL] [Abstract][Full Text] [Related]
3. Second-line Glucose-Lowering Therapy in Type 2 Diabetes Mellitus.
Shin JI
Curr Diab Rep; 2019 Jul; 19(8):54. PubMed ID: 31286271
[TBL] [Abstract][Full Text] [Related]
4. [Therapy of type 2 diabetes - Recommendations of the European Association for the Study of Diabetes (EASD)].
Müller-Wieland D; Marx N
Dtsch Med Wochenschr; 2020 May; 145(9):593-600. PubMed ID: 32349146
[TBL] [Abstract][Full Text] [Related]
5. [Management of hyperglycaemia of type 2 diabetes. Paradigm change according to the ADA-EASD consensus report 2018].
Scheen AJ; Paquot N
Rev Med Liege; 2018 Dec; 73(12):629-633. PubMed ID: 30570234
[TBL] [Abstract][Full Text] [Related]
6. [A revolution in the management of type 2 diabetes : antidiabetic agents providing a cardiovascular and renal protection independently of glucose control !].
Scheen AJ; Paquot N
Rev Med Liege; 2020 May; 75(5-6):392-398. PubMed ID: 32496686
[TBL] [Abstract][Full Text] [Related]
7. The position of SGLT2 inhibitors in current medicine.
Prázný M
Vnitr Lek; 2020; 66(2):82-88. PubMed ID: 32942881
[TBL] [Abstract][Full Text] [Related]
8. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
Davies MJ; D'Alessio DA; Fradkin J; Kernan WN; Mathieu C; Mingrone G; Rossing P; Tsapas A; Wexler DJ; Buse JB
Diabetologia; 2018 Dec; 61(12):2461-2498. PubMed ID: 30288571
[TBL] [Abstract][Full Text] [Related]
9. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
Davies MJ; D'Alessio DA; Fradkin J; Kernan WN; Mathieu C; Mingrone G; Rossing P; Tsapas A; Wexler DJ; Buse JB
Diabetes Care; 2018 Dec; 41(12):2669-2701. PubMed ID: 30291106
[TBL] [Abstract][Full Text] [Related]
10. 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
Buse JB; Wexler DJ; Tsapas A; Rossing P; Mingrone G; Mathieu C; D'Alessio DA; Davies MJ
Diabetes Care; 2020 Feb; 43(2):487-493. PubMed ID: 31857443
[TBL] [Abstract][Full Text] [Related]
11. [Evidence-based reduction of cardiovascular risk in patients with diabetes].
Schütt KA
Herz; 2020 Apr; 45(2):118-121. PubMed ID: 31820029
[TBL] [Abstract][Full Text] [Related]
12. Guideline recommendations and the positioning of newer drugs in type 2 diabetes care.
Marx N; Davies MJ; Grant PJ; Mathieu C; Petrie JR; Cosentino F; Buse JB
Lancet Diabetes Endocrinol; 2021 Jan; 9(1):46-52. PubMed ID: 33159841
[TBL] [Abstract][Full Text] [Related]
13. Risk factor reduction in type 2 diabetes demands a multifactorial approach.
Rydén L; Ferrannini G; Mellbin L
Eur J Prev Cardiol; 2019 Dec; 26(2_suppl):81-91. PubMed ID: 31766912
[TBL] [Abstract][Full Text] [Related]
14. [Combination therapy with SGLT2 inhibitor and GLP-1 receptor agonist in type 2 diabetes].
Scheen AJ
Rev Med Suisse; 2019 Aug; 15(659):1436-1441. PubMed ID: 31436058
[TBL] [Abstract][Full Text] [Related]
15. Metformin in patients with type 2 diabetes mellitus and heart failure: a review.
Kułaczkowska ZM; Wróbel M; Rokicka D; Gąsior M; Strojek K
Endokrynol Pol; 2021; 72(2):163-170. PubMed ID: 33970481
[TBL] [Abstract][Full Text] [Related]
16. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
Davies MJ; Aroda VR; Collins BS; Gabbay RA; Green J; Maruthur NM; Rosas SE; Del Prato S; Mathieu C; Mingrone G; Rossing P; Tankova T; Tsapas A; Buse JB
Diabetologia; 2022 Dec; 65(12):1925-1966. PubMed ID: 36151309
[TBL] [Abstract][Full Text] [Related]
17. Do published ADA studies support the ADA-EASD position statement for the management of hyperglycaemia in type 2 diabetics?
Rimareix F; Bauduceau B
Ann Endocrinol (Paris); 2013 Jul; 74(3):207-10. PubMed ID: 23747137
[TBL] [Abstract][Full Text] [Related]
18. [Extended indications for antidiabetic agents with cardio-renal protection in updated international recommendations for themanagement of at risk patients with type2 diabetes].
Scheen AJ; Paquot N
Rev Med Liege; 2020 Apr; 75(4):233-239. PubMed ID: 32267111
[TBL] [Abstract][Full Text] [Related]
19. Cardiorenal Protection: Potential of SGLT2 Inhibitors and GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes.
Nagahisa T; Saisho Y
Diabetes Ther; 2019 Oct; 10(5):1733-1752. PubMed ID: 31440988
[TBL] [Abstract][Full Text] [Related]
20. How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?: Completed and Ongoing Mechanistic Trials.
Lee MMY; Petrie MC; McMurray JJV; Sattar N
Arterioscler Thromb Vasc Biol; 2020 Mar; 40(3):506-522. PubMed ID: 31996025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
